Drug intelligence / Profile preview

CAT-1040

Development stage: Preclinical
Lead developer: Astria Therapeutics
Modality: Small Molecules

Overview

**CAT-1040** is an investigational small-molecule drug developed by Catabasis Pharmaceuticals for muscular dystrophy, specifically targeting inflammation in muscle tissue to improve muscle function. It belongs to a series of compounds including CAT-1004, evaluated in preclinical models of muscle disorders. Limited public data is available on its precise mechanism of action, modality details, or clinical advancement beyond early-stage research supported by grants such as from the Muscular Dystrophy Association.

Beyond the preview

Go deeper on CAT-1040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAT-1040.

Explore the full profile